Other equities analysts have also issued reports about the stock. JMP Securities restated a market outperform rating and issued a $4.00 price target on shares of DBV Technologies in a research report on Tuesday, August 1st. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of DBV Technologies in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of Hold and an average price target of $7.00.
DBV Technologies Trading Down 1.3 %
DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its quarterly earnings results on Monday, July 31st. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $1.00 million. Equities analysts forecast that DBV Technologies will post -0.54 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Braidwell LP acquired a new stake in shares of DBV Technologies in the 4th quarter valued at $18,525,000. VR Adviser LLC acquired a new position in shares of DBV Technologies in the 4th quarter worth approximately $29,258,000. Point72 Asset Management L.P. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at about $5,914,000. Millennium Management LLC lifted its stake in shares of DBV Technologies by 53.9% in the 4th quarter. Millennium Management LLC now owns 871,996 shares of the company’s stock valued at $1,334,000 after purchasing an additional 305,562 shares during the period. Finally, ExodusPoint Capital Management LP acquired a new position in shares of DBV Technologies during the 2nd quarter valued at $352,000. Institutional investors and hedge funds own 23.90% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.
- Five stocks we like better than DBV Technologies
- What Is WallStreetBets and What Stocks Are They Targeting?
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How to Invest in Insurance Companies: A Guide
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- How to Buy Gold Stock and Invest in Gold
- The Top 5 Analysts Calls in September
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.